<DOC>
	<DOCNO>NCT00152451</DOCNO>
	<brief_summary>This trial evaluate efficacy safety ucb 44212 add therapy subject focal epilepsy .</brief_summary>
	<brief_title>Study With Seletracetam ( Ucb 44212 ) Adult Subjects ( 18 65 Years ) With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Males/Females 18 65 year age ( minimum body weight 40 kg ) Subjects confirm diagnosis epilepsy suffer partial onset seizures whether secondarily generalize . Subjects treat epilepsy â‰¥6 month currently uncontrolled treat 13 concomitant AED ( ) . Female subject without childbearing potential ; Female subject childbearing potential eligible use medically accept nonhormonal contraceptive method Seizures occur cluster . Status epilepticus within 6 month Visit 1 . History nonepileptic seizure Subjects vigabatrin Subjects felbamate , unless treatment continuous &gt; 2 year Ongoing psychiatric disease mild control disorder . Subjects clinically significant organ dysfunction Known allergic reaction intolerance pyrrolidine derivative and/or excipients Pregnant lactating woman . Subjects currently take levetiracetam ( LEV ) . Use benzodiazepine ( indication ) take high frequency average week , unless count one concomitant AEDs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy : partial onset seizure , seletracetam</keyword>
</DOC>